Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IN006 RSV Vaccine in Older Adults
NCT07128121Phase 2Active, not recruiting
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Oct 2029
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IN006 in respiratory syncytial virus infection (RSV), sponsored by Shenzhen Shenxin Biotechnology Co., Ltd.. Started Aug 2025; status: active, not recruiting.
02
Drugs
IN006
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07128121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128121.